Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Dec 15, 2014; 5(6): 777-786
Published online Dec 15, 2014. doi: 10.4239/wjd.v5.i6.777
Published online Dec 15, 2014. doi: 10.4239/wjd.v5.i6.777
Diabetes mellitus and cellular replacement therapy: Expected clinical potential and perspectives
Alexander E Berezin, Department of Internal Medicine, State Medical University, 69035 Zaporozhye, Ukraine
Author contributions: Berezin AE solely contributed to this paper.
Correspondence to: Alexander E Berezin, MD, PhD, Professor, Chief of Cardiology Unit, Department of Internal Medicine, State Medical University, 26, Mayakovsky av., 69035 Zaporozhye, Ukraine. dr_berezin@mail.ru
Telephone: +380-6-12894585 Fax: +380-6-12894585
Received: May 29, 2014
Revised: July 16, 2014
Accepted: September 23, 2014
Published online: December 15, 2014
Processing time: 197 Days and 21.8 Hours
Revised: July 16, 2014
Accepted: September 23, 2014
Published online: December 15, 2014
Processing time: 197 Days and 21.8 Hours
Core Tip
Core tip: Modern approaches to stem cell therapy are discussed a promising component of treatment program in diabetes mellitus. It is important to emphasize that the new technology that is associated with reprogramming of stem cells has a couple of disputes in accordance with the ethical considerations and practical issues. However, the extremely high cost of novel methods toward preventing immune rejection of graft tissue and the high risk of oncogenesis retain their value as major constraints to the implementation into routine clinical practice. The purpose of the review was to summarize and analyze data for existing knowledge and prospects for future researches in the field of regenerative therapy in patients with diabetes mellitus.